Prevention of Hemophilus influenzae type b disease
J. Band, D. Fraser, и G. Ajello. JAMA: The Journal of the American Medical Association, 251 (18):
2381--6(мая 1984)PMID: 6368889.
Аннотация
To determine the efficacy of rifampin prophylaxis in eradication of oropharyngeal carriage of Hemophilus influenzae type b and prevention of secondary H influenzae type b disease, we conducted a multicenter placebo-controlled trial among selected persons with invasive H influenzae type b disease. Households and day-care classrooms were randomized so that their members received either rifampin (initially at a dose of 10 mg/kg/dose for two to four days rifampin-10, but subsequently at 20 mg/kg/dose for four days rifampin-20) or placebo. Pretherapy H influenzae type b colonization rates were similar in the treatment groups. Therapy with either rifampin regimen significantly reduced carriage (rifampin-20, 97\%; rifampin-10, 63\%; placebo, 28\%). New acquisition of carriage was also significantly reduced by either rifampin regimen (rifampin-20 or rifampin-10, 2\% v placebo, 6\%). No rifampin-resistant H influenzae type b isolates emerged after treatment. Four of 765 placebo-treated contacts experienced secondary disease in contrast to zero of 1,112 rifampin-treated contacts. Because chemoprophylaxis of close contacts with rifampin seems to reduce significantly the risk of secondary H influenzae type b disease, we recommend the administration of prophylaxis in households or day-care classrooms where children younger than 4 years have been exposed to the disease.
%0 Journal Article
%1 band_prevention_1984
%A Band, J D
%A Fraser, D W
%A Ajello, G
%D 1984
%J JAMA: The Journal of the American Medical Association
%K Adolescent, Age Care Carrier Centers, Child Child, Clinical Day Factors, Female, Haemophilus Humans, Infant, Infections, Male, Method, Preschool, Rifampin State, Topic, Trials as influenzae, {Double-Blind}
%N 18
%P 2381--6
%T Prevention of Hemophilus influenzae type b disease
%U http://www.ncbi.nlm.nih.gov/pubmed/6368889
%V 251
%X To determine the efficacy of rifampin prophylaxis in eradication of oropharyngeal carriage of Hemophilus influenzae type b and prevention of secondary H influenzae type b disease, we conducted a multicenter placebo-controlled trial among selected persons with invasive H influenzae type b disease. Households and day-care classrooms were randomized so that their members received either rifampin (initially at a dose of 10 mg/kg/dose for two to four days rifampin-10, but subsequently at 20 mg/kg/dose for four days rifampin-20) or placebo. Pretherapy H influenzae type b colonization rates were similar in the treatment groups. Therapy with either rifampin regimen significantly reduced carriage (rifampin-20, 97\%; rifampin-10, 63\%; placebo, 28\%). New acquisition of carriage was also significantly reduced by either rifampin regimen (rifampin-20 or rifampin-10, 2\% v placebo, 6\%). No rifampin-resistant H influenzae type b isolates emerged after treatment. Four of 765 placebo-treated contacts experienced secondary disease in contrast to zero of 1,112 rifampin-treated contacts. Because chemoprophylaxis of close contacts with rifampin seems to reduce significantly the risk of secondary H influenzae type b disease, we recommend the administration of prophylaxis in households or day-care classrooms where children younger than 4 years have been exposed to the disease.
@article{band_prevention_1984,
abstract = {To determine the efficacy of rifampin prophylaxis in eradication of oropharyngeal carriage of Hemophilus influenzae type b and prevention of secondary H influenzae type b disease, we conducted a multicenter placebo-controlled trial among selected persons with invasive H influenzae type b disease. Households and day-care classrooms were randomized so that their members received either rifampin (initially at a dose of 10 mg/kg/dose for two to four days [rifampin-10], but subsequently at 20 mg/kg/dose for four days [rifampin-20]) or placebo. Pretherapy H influenzae type b colonization rates were similar in the treatment groups. Therapy with either rifampin regimen significantly reduced carriage (rifampin-20, 97\%; rifampin-10, 63\%; placebo, 28\%). New acquisition of carriage was also significantly reduced by either rifampin regimen (rifampin-20 or rifampin-10, 2\% v placebo, 6\%). No rifampin-resistant H influenzae type b isolates emerged after treatment. Four of 765 placebo-treated contacts experienced secondary disease in contrast to zero of 1,112 rifampin-treated contacts. Because chemoprophylaxis of close contacts with rifampin seems to reduce significantly the risk of secondary H influenzae type b disease, we recommend the administration of prophylaxis in households or day-care classrooms where children younger than 4 years have been exposed to the disease.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Band, J D and Fraser, D W and Ajello, G},
biburl = {https://www.bibsonomy.org/bibtex/2977a20a4d5552fe4873b22dd9e3e39ad/jelias},
interhash = {ad80d12b2978c9eee6b2d88224824365},
intrahash = {977a20a4d5552fe4873b22dd9e3e39ad},
issn = {0098-7484},
journal = {{JAMA:} The Journal of the American Medical Association},
keywords = {Adolescent, Age Care Carrier Centers, Child Child, Clinical Day Factors, Female, Haemophilus Humans, Infant, Infections, Male, Method, Preschool, Rifampin State, Topic, Trials as influenzae, {Double-Blind}},
month = may,
note = {{PMID:} 6368889},
number = 18,
pages = {2381--6},
timestamp = {2011-03-11T10:05:48.000+0100},
title = {Prevention of Hemophilus influenzae type b disease},
url = {http://www.ncbi.nlm.nih.gov/pubmed/6368889},
volume = 251,
year = 1984
}